Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seladelpar in Primary Biliary Cholangitis and Compensated Cirrhosis
NCT06051617Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Sep 2023
- Primary completion
- Aug 2030
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of seladelpar in primary biliary cholangitis (PBC), sponsored by Gilead Sciences. Started Sep 2023; status: recruiting.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06051617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06051617.